Jagdish Butany, MBBS, MS, FRCPC, Department of Pathology, Toronto General Hospital, University Health Network; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto ...

Cardiac catheterization helps exclude coronary disease as the cause of angina in patients with risk factors for coronary atherosclerosis. [5] It can also be used to measure LV outflow tract ...

Aim Differentiating physiological cardiac hypertrophy from pathology is challenging when the athlete presents with extreme ... Three athletes were diagnosed with a cardiomyopathy (0.4% prevalence); ...

claiming a green light from the US regulator for mavacamten as a therapy for obstructive hypertrophic cardiomyopathy (HCM). Orally-active mavacamten – which was acquired by BMS when it bought ...